Appili Therapeutics Inc. (TSX:APLI)
0.0150
0.00 (0.00%)
Jun 3, 2025, 10:43 AM EDT
Appili Therapeutics Revenue
Appili Therapeutics had revenue of 108.36K CAD in the quarter ending December 31, 2024, a decrease of -77.35%. This brings the company's revenue in the last twelve months to 124.75K, down -89.15% year-over-year. In the fiscal year ending March 31, 2024, Appili Therapeutics had annual revenue of 827.41K with 147.60% growth.
Revenue (ttm)
124.75K
Revenue Growth
-89.15%
P/S Ratio
14.58
Revenue / Employee
n/a
Employees
9
Market Cap
1.82M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
dentalcorp Holdings | 1.58B |
Sienna Senior Living | 896.45M |
Green Thumb Industries | 1.64B |
Extendicare | 1.47B |
Cronos Group | 179.08M |
Trulieve Cannabis | 1.71B |
WELL Health Technologies | 990.34M |
Curaleaf Holdings | 1.89B |
Appili Therapeutics News
- 5 days ago - Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. - GlobeNewsWire
- 16 days ago - Aditxt to terminate arrangement agreement with Appili Therapeutics - Seeking Alpha
- 16 days ago - Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - GlobeNewsWire
- 4 weeks ago - Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia - GlobeNewsWire
- 5 weeks ago - Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™ - GlobeNewsWire
- 2 months ago - Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 - GlobeNewsWire
- 2 months ago - Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update - GlobeNewsWire
- 3 months ago - Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025 - GlobeNewsWire